No aid for sleepless in Paris
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Aventis received an FDA "complete response" letter for its novel insomnia candidate eplivanserin, the firm announced Sept. 16. The firm said only that FDA is asking for additional information regarding the benefit-risk profile of the serotonin type 2A receptor antagonist. Sanofi is seeking approval to treat patients with chronic insomnia characterized by difficulties with sleep maintenance, a unique claim that could help distinguish a new entrant in a crowded market. The setback is especially critical because the firm faces generic competition for its big money maker in the insomnia market, Ambien, which went off patent in 2007 and saw the launch of its first branded competitor Edular earlier in September by Meda Pharmaceuticals (2"The Pink Sheet" DAILY, Sept. 9, 2009). Sanofi previously had a back-up compound in development - volinanserin - but terminated clinical trials after the compound failed to show efficacy in primary insomnia with predominant sleep maintenance problems
You may also be interested in...
Meda's Edluar Is First Alternative Form of Generic Ambien To Hit Insomnia Market
Lozenge form of zolpidem tartrate is the first of several new versions of Ambien that could launch in the coming months.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.